Biodexa Flags Going Concern Risk as Cash Dwindles to £3.2M
BDRX has more than doubled off its 52-week low of $0.61 on elevated volume (52× avg).
Summary
Biodexa's interim results reveal a cash balance of £3.23 million at June 30, 2026, down from £8.53 million at year-end, with net cash used in operations of £4.61 million for the half. The company explicitly states that further financing will be required during Q4 2026 and that this represents a material uncertainty casting significant doubt on its ability to continue as a going concern. R&D spending jumped 75% to £2.92 million, driven by the Serenta Phase 3 trial and the newly in-licensed MTX240 program, while administrative costs fell 27% to £1.74 million. The company completed a $3.5 million raise on July 1, 2026, but that only extends the runway modestly. With a market cap below $1 million and Nasdaq's proposed minimum market value rule looming, the financing risk is acute. The Serenta trial has enrolled 92 of 168 subjects, and the NMIBC Phase 2 readout is expected in Q4 2026, but the immediate concern is whether Biodexa can secure additional capital before its cash runs out.
At the time of this announcement, BDRX was trading at $1.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $679.3K. The 52-week trading range was $0.61 to $59.40. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.